ESG Report 2022

The Group's research team has conducted thorough specifications of Sodium Hyaluronate Eye Drops research on the pharmacological quality and also obtained the drug registration certificate and bioequivalence of the drugs in conjunction with the passed the consistency evaluation on the quality and technical requirements of the drug marketing efficacy of generic drugs. The Group's competitive application and the consistency evaluation of edge in the market has been gradually enhanced generic drugs to ensure that the drugs meet the from several products passing the consistency requirements of safety, efficacy and quality control. evaluation on the quality and efficacy of generic drugs. Currently, the Group has a total of 11 products During the reporting period, the Group's Biapenem that have passed (including deemed passing) the for Injection, Cefuroxime Axetil Tablets and consistency evaluation. The Group will continue Piperacillin Sodium and Tazobactam Sodium for promoting the consistency evaluation of generic Injection passed the consistency evaluation on the drugs to provide patients with more choices in quality quality and efficacy of generic drugs, while 2 drugs. TUL01101 Ointment is a topical preparation of Janus Kinase (JAK) inhibitor for the treatment of mild to moderate atopic dermatitis with proven efficacy and fewer side effects. JAK inhibitor drugs include oral preparations and topical skin preparations. Compared with the oral preparation, JAK inhibitor topical preparation can achieve high retention of the drug in the skin, while reducing the systemic absorption of the drug, resulting in high efficacy and less adverse reactions, thus enhancing the safety. To date, only a few topical JAK inhibitor preparations have been approved for marketing in overseas markets, and no such product has been approved in China market. Several Products Passing the Consistency Evaluation of Generic Drugs R&D of Innovative Drugs TUL01101 Ointment Being Approved for Clinical Trials TUL12101 Eye Drops Being Accepted for the Trial Application Environmental, Social and Governance Report 2022 The United Laboratories International Holdings Limited 15 TUL12101 is a new generation of small molecule RASP (Reactive Aldehyde Specie) inhibitor developed by the Company for the treatment of dry eye syndrome. RASP is a pro-cytokine mediator of inflammation. By binding to thiol and amine residues on proteins, it enhances the release of cytokines and activates inflammasomes, and it can also bind to class A scavenger receptors (SR- A1/CD204) to produce pro-inflammatory effects. As a RASP inhibitor, TUL12101 can covalently bind free aldehydes and reduce excessive RASP levels, rapidly reduce the content of active aldehydes in the eye, relieve inflammation and break the vicious cycle of inflammation, thereby achieving the purpose of treating dry eye syndrome. At present, there are no other products with the same mechanism on the market in China or abroad.